Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib add-on therapy for immuno-metabolic depression in major depressive disorder
NL-OMON59155Phase 3Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Celecoxib + treatment as usual with Placebo + treatment as usual (2 arms). Primary endpoint: Inventory of Depressive Symptomatology total score. Started Oct 2024; status: completed.
02
Drugs
celecoxib
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON59155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59155.